Recurrent Non-small Cell Lung Cancer Recruiting Phase 2 Trials for Alectinib (DB11363)

Also known as: Non-Small Cell Lung Cancer Recurrent / Lung cancer non-small cell recurrent

IndicationStatusPhase
DBCOND0028805 (Recurrent Non-small Cell Lung Cancer)Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03445000ALEctinib for the Treatment of Pretreated RET-rearranged Advanced Non-small Cell Lung Cancer Treatment of Pretreated RET-rearranged Advanced NSCLCTreatment